Contineum Therapeutics, Inc.
CTNMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Contineum Therapeutics, Inc. focuses on Biotechnology services and products. Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in. With a market capitalization of $628.3M, it sits in small-cap territory. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Market Cap
$628.3M
Beta
0.75
P/E (TTM)
—
P/E (Fwd)
-9.29
EPS (TTM)
$-1.72
EPS (Fwd)
$-1.80
ROE
-28.0%
ROA
-19.1%
Cash
$236.6M
Total Debt
$6.6M
Free CF
-$35.1M
52W Change
33.4%
Annual Financials
Cash vs Debt
Where CTNM stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, CTNM finished 19.55% above its 150-day moving average ($13.91) and 25.60% above its 200-day moving average ($13.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTNM overbought or oversold?
At the August 25, 2026 close, CTNM's RSI(14) was 55.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Contineum Therapeutics, Inc. holds $236.6M in cash against $6.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$35.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -28.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, CTNM has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Contineum Therapeutics, Inc.'s trajectory.